Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biofrontera Inc. filings document a Nasdaq-listed dermatology biopharmaceutical company focused on photodynamic therapy. The company’s Form 8-K reports cover financial results, preliminary revenue updates, clinical disclosures for Ameluz PDT programs, patent-related proceedings, and Nasdaq continued-listing compliance notices. Its registered securities include common stock under BFRI and warrants under BFRIW.
Proxy materials describe board elections, stockholder voting matters, equity incentive plan approvals, auditor ratification, and governance procedures. The filing record also reflects disclosure controls around non-GAAP financial measures, Regulation FD announcements, risk-related litigation and patent matters, and capital-structure items such as warrants and preferred stock purchase rights.
Heikki Lanckriet, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to purchase 20,000 shares of common stock at an exercise price of $1.00 per share. The option shows an exercise/vesting reference date of 07/22/2025 and an expiration date of 07/22/2035. The filing states the option vests in twelve equal monthly installments beginning on August 22, 2025. Following the grant, the report lists 20,000 underlying shares as beneficially owned by Mr. Lanckriet on a direct basis.
Beth J. Hoffman, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to buy 20,000 shares of common stock at an exercise price of $1.00 per share. The option becomes exercisable in monthly installments beginning August 22, 2025 and vests over twelve equal monthly installments; the option expires on July 22, 2035. The Form 4 was signed by an attorney-in-fact on September 16, 2025. The filing reports the grant as a direct beneficial ownership of 20,000 underlying shares.
John J. Borer III, a director of Biofrontera Inc. (BFRI), reported a non-derivative change dated 07/22/2025. The filing shows an employee stock option transaction: 20,000 options with a $1 exercise price, exercisable on 07/22/2025 and expiring on 07/22/2035. Following the reported transaction, 20,000 shares of common stock are shown as beneficially owned directly. The option vests in twelve equal monthly installments beginning 08/22/2025. The form is signed by Daniel Hakansson as attorney-in-fact for Mr. Borer on 09/16/2025.